Step 1

Draft

Step 2

Unite with Fellow Investors

Step 3

Choose the Best Attorney

Step 4

Provide Documents

Step 5

Follow Case Progress

Step 6

Get Payout

BAYRY.US

id: 1652

Bayer ($BAYRY) $38M Investor Settlement

Late claims are being considered for compensation, subject to approval.

$38,000,000

Cash Settlement

N.D. California

Court

3:20-cv-04737

Case number

05/23/2016

Class period Start

07/06/2020

Class period End

10/16/2025

Claim deadline

Bayer ($BAYRY) has agreed to settle $38 million with investors to resolve claims that it misled them about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation.

Outline:

Bayer announced plans to acquire Monsanto as part of a major expansion in the agricultural chemicals market. Investors later alleged the company failed to disclose the full scope of litigation risks tied to Roundup. After several jury verdicts in Roundup cancer trials raised concerns about those risks, the stock declined. Investors filed suit and Bayer later agreed to a $38 million settlement.

Timeline:
May 23, 2016: Bayer announced plans to acquire Monsanto for $122 per share.
June 2018: Bayer completed the $63 billion acquisition of Monsanto.
August 10, 2018: A California jury awarded $289 million in the first Roundup cancer trial.
March 19, 2019: After another adverse verdict, $BAYRY declined about 11%.
July 15, 2020: Investors filed a securities class action lawsuit against Bayer.
April 23, 2025: Bayer agreed to a $38 million settlement to resolve the claims.
Background:

Bayer is a multinational pharmaceutical and agricultural company that acquired Monsanto in 2018 in a transaction valued at approximately $63 billion. The acquisition was intended to expand Bayer’s position in the global agricultural chemicals and seed markets.

Before completing the transaction, Bayer stated that it had conducted due diligence regarding potential legal risks associated with Monsanto’s products, including Roundup, a widely used herbicide containing glyphosate.

Shortly after the acquisition closed, several U.S. jury verdicts found that Roundup exposure contributed to cases of non-Hodgkin’s lymphoma. These rulings raised concerns about the scale of potential litigation exposure tied to the product.

Investors later alleged that Bayer did not adequately disclose the extent of the litigation risks associated with the acquisition. Following the trial verdicts and related developments, Bayer’s share price declined and shareholders filed a securities class action lawsuit.

What Can Investors Expect Now?

Bayer agreed to a $38 million settlement with $BAYRY investors to resolve claims that it misled them about legal risks associated with its acquisition of Monsanto.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.

Case Type

US Securities Class Action

Case Status

Accepting Late Claims

Alleged Offence

Misleading Statements,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Depository Securities (ADS, ADR, GDR)

Trade Direction

Long

Payout per Share

0.23

Filing date

07/15/2020

Plaintiffs

SHEET METAL WORKERS’ NATIONAL PENSION FUND

Attorneys

Robbins Geller Rudman & Dowd LLP; Motley Rice LLC

Defendants

Werner Baumann; Wolfgang Nickl; Liam Condon

Administrator

EPIQ

Court hearing date

10/30/2025

Exclusion deadline

10/09/2025

Objection deadline

10/09/2025

Hearing deadline

10/30/2025

Attorney fee

$13,810,000

Trades matching type

FIFO

Frequently Asked Questions

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.